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Next-Generation in vivo Modeling of
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Gaetano Gargiulo*
Molecular Oncology, Max Delbrück Center for Molecular Medicine, Berlin, Germany
Animal models of human cancers played a major role in our current understanding
of tumor biology. In pre-clinical oncology, animal models empowered drug target and
biomarker discovery and validation. In turn, this resulted in improved care for cancer
patients. In the quest for understanding and treating a diverse spectrum of cancer
types, technological breakthroughs in genetic engineering and single cell “omics” offer
tremendous potential to enhance the informative value of pre-clinical models. Here, I
review the state-of-the-art in modeling human cancers with focus on animal models for
human malignant gliomas. The review highlights the use of glioma models in dissecting
mechanisms of tumor initiation, in the retrospective identification of tumor cell-of-origin,
in understanding tumor heterogeneity and in testing the potential of immuno-oncology. I
build on the deep review of glioma models as a basis for a more general discussion of
the potential ways in which transformative technologies may shape the next-generation
of pre-clinical models. I argue that refining animal models along the proposed lines will
benefit the success rate of translation for pre-clinical research in oncology.
Keywords: mouse models, cancer, single-cell genomics, CRISPR/Cas9, targeted therapies, biomarker discovery,
preclinical models, patient-derived xenografts (PDX)
INTRODUCTION
Modeling human tumors in animals has been the leading approach to translational research in
oncology over the last three decades. Successes in the field include, among others, identifying
druggable targets for aggressive subtypes of leukemia, breast cancer and melanoma. In the late
1990s, the retinoic acid (RA) was successful to induce full remission in 71–91% of patients with
acute promyelocytic leukemia (APL) in clinical trials that compared this treatment with standard
chemotherapy (1). The first transgenic murine models for human APL were generated by inserting
the oncogene PML-RAR in promyelocytes downstream the Cathepsin G or hMPR8 regulatory
elements (2, 3). These models showed sensitivity to RA (4) confirming their value in the treatment
of APL and making them the leading models to investigate responses to anti-cancer treatments at
the cellular and molecular levels.
In solid tumors, Trastuzumab (clinical name Herceptin) was approved for treatment in Her2
positive breast cancer. Trastuzumab is an antibody binding to the EGF receptor Her2 and clinical
trials showed benefit in Her2 positive breast cancer patients in terms of progression-free and overall
survival (5). When the murine p185 antibody was tested in murine breast cancer xenograft models,
it proved to be effective in counteracting tumor growth (6). Shortly afterwards, the murine Her2
antibody was humanized to allow its use in clinical trials (7).
Kinase inhibitors were considered the poster child of targeted therapies in the early
2000s and several were approved for treating different malignancies. Imatinib (clinical name,
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Gleevec) was approved to block the signaling activity of the
BCR-ABL fusion protein oncogene in Chronic myeloid leukemia
(CML) (8). In mice, the dependence for CML cells on BCR-ABL
and the main features of response and resistance to Imatinib
could be successfully demonstrated (9). In addition to mouse
models, larger animal models such a spontaneous Canine B-
cell Lymphoma have also been used to validate the therapeutic
outlook for kinase inhibitors (10). The Ibrutinib, a Bruton’s
tyrosine kinase (BTK) inhibitor validated in this way, later
showed a durable efficacy in relapsed or refractory mantle cell
lymphoma patients as single agent (11), or in combination with
an anti-CD20 antibody (clinical name, Rituximab) (12), which
was later extended to chronic lymphocytic leukemia (13).
In the case of the specific BRAFV600E inhibitor Vemurafinib
(14), preclinical models not only validated the response to BRAF
inhibition but also revealed the RAF paradox, meaning that ERK
signaling is amplified by RAF inhibition in BRAF-wild-type, RAS
mutant tumors, despite RAF’s position downstream RAS (15).
In Non-Small Cell Lung cancer (NSCLC), Crizotinib showed
great anti-tumor potential against EML4-ALK fusion positive
carcinomas, and it has quickly gained momentum for treating a
subset of NSCLC patients (16), after successful evaluation in a
transgenic mouse model for lung adenocarcinoma (17).
Despite the great success of those compounds, which benefits
many cancer patients, targeted therapies are accompanied by
acquired resistance, when cancer cells experience gatekeeper
mutations or activate alternative pro-tumorigenic pathways
(18, 19). To overcome this limitation, targeted therapies
are combined with standard chemotherapy or combinations
of targeted therapies are sought in appropriate pre-clinical
settings (20).
In the clinics, drug combinations often aim at extending
on-target toxicity by targeting the same mechanisms (i.e.,
unrestricted proliferation) with multiple drugs. For instance,
the combination of four different chemotherapeutic agents
Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD)
is the standard of care in the treatment of Hodgkin lymphoma
(21). However, the use of multiple drugs is accompanied by
the increased burden of side effects for patients. Testing more
sophisticated approaches, such as synthetic lethality in animal
models represents therefore the ideal pre-clinical development.
Synthetic lethality is a concept originated from yeast biology
and reflects the observation that simultaneously hitting two
closely related mechanisms can lead to significant toxicity,
whereas single treatments are largely well-tolerated. This offers
the possibility to target cancer cells bearing specific alterations,
sparing normal cells from side effects. The paradigm of a
synthetic-lethal treatment that has made its way into clinical
application is the use of Poly-(ADP-ribose) polymerase (PARP)
inhibitors in ovarian cancer and breast cancer (22). Targeting
PARP proved to be synthetic lethal with concurrent alterations
in homologous recombination (HR) DNA repair genes, such
as BRCA1 and BRCA2. In pre-clinical research, BRCA-mutant
mouse models have been instrumental in highlighting the
strength of these treatments and have illustrated potential ways
to circumvent their limitations (23). Clinical trials have led to
the FDA approval of a number of PARP inhibitors showing
efficacy in treatments for ovarian, breast and prostate cancer.
In a BRCA-competent triple negative breast cancer/TNBC)
DDR-mediated PARP antitumor activity was reinforced by
concurrent PI3K-AKT-mTor pathway inhibition (24). In general,
predicting long-term responders to PARP inhibitors is a
critical issue that has yet to be solved by future pre-clinical
breakthroughs.
In addition to their roles as discovery platforms, accurate
pre-clinical models can also predict patients’ response to a
given treatment. In a seminal study, Singh et al. retrospectively
assessed targeted therapies either alone or in combination
with standard-of-care treatments thereby replicating large-scale
human clinical trials (25). This was achieved by applying a similar
treatment protocol and evaluating the clinical endpoints overall
survival (OS) and progression free survival (PFS) for in vivo
studies. Animal models for pancreatic ductal adenocarcinoma
(PDAC) and non-small cell lung cancer (NSCLC) were exploited
as surrogate for KRASG12D patients’ response to Erlotinib
and Bevacizumab, therapeutics targeting epidermal growth
factor (EGFR) and vascular endothelial growth factor (VEGF),
respectively. The standard of care (Carboplatin or Gemcitabine)
was combined with targeted drugs thereby mimicking the
original studies (25). Retrospectively, this post-clinical study
obtained (largely negative) results comparable to those for
human clinical trials. This set an excellent standard for future
design of pre-clinical studies.
Currently, technological breakthrough in the field of genetic
engineering and single cell genomics are enabling us to create
ever-more sophisticated animal models of human cancers, and
to exploit them in achieving a better translation of pre-clinical
studies. Here, I focus on animal models for human malignant
gliomas as an entry point for a retrospective review of the use
of animal models in tumor biology and therapy. Thereafter, I
review state-of-the-art technologies and offer future perspective
to incorporating these in generating and exploiting animal
models as pre-clinical tools for cancer biology and intervention,
which can be valid for glioma and more in general for different
types of human cancer.
EXPERIMENTAL MODELS FOR
HIGH-GRADE GLIOMAS
Autochthonous Mouse Models
Autochthonous mouse models for human cancers are obtained
by initiating tumors in a normal cell de novo and within the
intact organism. The main advantage of these models is the
pathophysiological relevance of the tumor initiation.
Mouse models for Glioblastoma Multiforme (GBM) have
been systematically used to investigate tumor initiation and
progression in the context of a living organism. The first example
of genetically engineered mouse models (GEMMs) in modeling
gliomas was developed in the Aguzzi lab. It was generated
through the over-expression of the v-Src oncogene via the glial
fibrillary acidic protein (GFAP) regulatory elements (26). Later,
Holland and Varmus introduced to the scientific community a
model based on avian retroviral gene transfer, the RCAS-TVA,
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TABLE 1 | Autochthonous mouse models for glioma.
Genetic alterations Cell type
specificity
Potential cell of
origin
Selected conclusion(s) References
v-Src (gain) GFAP Astrocytes Glioma formation driven by v-Src expression in
astrocytes
Weissenberger et al. (26)
EGFRvIII (gain); p16, p19 (loss) GFAP, Nestin Astrocytes and
NPCs
Patient-specific alterations are capable of
transformation; NPCs are more prone to
transformation
Holland et al. (27)
AKT-Myr 111–60 KRASG12D Nestin NPCs RAS and AKT signaling cooperatively but not
exclusively are capable of transforming NPCs.
Holland et al., (28)
NF1, Trp53 (loss) ubiquitous Astrocytes and
NPCs
Spontaneous gliomagenesis in animals with tumor
suppressors deficient background; role for genotype
in spontaneous tumor formation.
Reilly et al. (29)
GFAP-HRASG12V GFAP Astrocytes Supraphysiological RAS activation in astrocytes can
lead to pathologically-relevant alterations
Ding et al., (30)
v-erbB (EGFR; gain); Trp53, p16,
p19 (loss)
S100B Glial cells Overexpression of v-erbB (EGFR) induces
oligodendroglioma and GBM in combination with
p53 or CDKN2A deletion; spontaneous loss of
chromosomal DNA synthenic to human
chromosome 1p
Weiss et al., (31)
NF1 (loss) GFAP
KO+ubiquitous
HET
Astrocytes spontaneous optic nerve glioma formation in
animals in which NF1 is biallelically deleted in
astrocytes as well as heterozygously inactivated in
the microenvironment
Bajenaru et al., (32)
NF1, Trp53 (loss) GFAP NPCs Complete penetrance for NF1 and p53 mutant
gliomas; evidence for NSC as cell of origin for
gliomas
Zhu et al., (33)
NF1, Trp53, PTEN (loss) GFAP NPCs AKT activation driven by PTEN loss coorelated with
GBM grading in the mouse tumors
Kwon et al., (34)
v-erbB (EGFR); Trp53 KO S100B Astrocytes and
OPCs
Evidence for Side-population cancer stem-like cells
in a mouse model for oligodentroglioma
Harris et al., (35)
hPDGF-B GFAP Astrocytes and
spinal cord
Tet-inducible model for spinal oligoastrocytoma Hitoshi et al., (36)
PDGF-B-IRESβGeo; p53−/−; GFAP Astrocytes PDGF stimulation and p53 loss induce tumors in
diferent parts of the brain
Hede et al., (37)
RB, p53, PTEN GFAP NPCs Inactivation of different combinations of tumor
suppressor genes in SVZ causes brain tumors with
different phenotypes
Jacques et al. (38)
NF1, Trp53 (loss) GFAP, Nestin or
NG2
NPCs and OPCs OPCs can serve as cell of origin for gliomas Liu et al., (39)
PTEN, p53 retroviral activation NPCs PDGF stimulation and deletion of PTEN and p53
lead to a Proneural-like expression phenotype
Lei et al., (40)
HRASV12 lentiviral GFAP
activation
Astrocytes and
NPCs
Gliomagenesis is more effective in the hippocampus
and the subventricular zone than in the cortex
Marumoto et al., (41)
INK4A/ARF; KRASv12PTEN;
INK4A/ARF; KRASv12 p53;
INK4A/ARF; KRASv12
lentiviral CMV or
GFAP activation
Astrocytes and
NPCs
Higher penetrance and faster gliomagenesis in
CMV- vs. GFAP-lenti-Cre activated mutations.
de Vries et al., (42)
PTEN, TP53, and RB1 GFAP Astrocytes and
NPCs
PTEN or RB deletion drive somatic amplifications of
genes in the PI3K or Rb pathways
Chow et al. (43)
NF1, Trp53 (loss) SynI-Cre,
GFAP-Cre,
Nes-Cre
Neurons,
Astrocytes and
NPCs
Neurons can be transformed by delivery of shRNAs
targeting NF1 and p53. Dedifferentiation toward
NPCs is pbserved in targeted matureastrocytes.
Friedmann Morvinski et al. (44)
p53, PTEN, NF1 Nestin NSCs CSCs can exploit quiescence similar to adult neural
stem cells (NSCs) to contribute to relapse after
chemotherapy.
KRAS and AKT or
PDGFB in ARF−/− and
INK4A/ARF−/−
CNP+ SVZ OPCs KRAS & AKT or PDGFB dictates astrocytic or
oligodendroglial tumor development from OPCs
Lindberg et al. (45)
p53, PTEN, NF1 Ascl1 or Ng2 Astrocytes, NPCs,
or OPCs
The cell of origin emerges as a major determinant of
GBM molecular subtype
Alcantara Llaguno et al. (46)
(Continued)
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TABLE 1 | Continued
Genetic alterations Cell type
specificity
Potential cell of
origin
Selected conclusion(s) References
p53, PTEN, NF1 electroporation
delivery
NPCs Cas9 and sgRNAs delivered to the cerebral
verntricular zone lead to transformation
Zuckermann et al. (47)
RBP-JK, p53 Hes5 NPCs Notch signaling is tumor suppressive and
contributes to the formation of primitive
neuroectodermal-like lesions
Giachino et al. (48)
BCAN-NTRK1 fusion protein adenoviral delivery NPCs Expression of the EML4-ALK fusion protein drives
gliomagenesis
Cook et al. (49)
56 (brain) tumor suppressors adenoviral delivery astrocytes PTEN mutations enhances resistance to therapy in
RB1 mutated glioma
Chow et al. (50)
PDGF-B; ARF−/− GFAP+ SVZ,
CNP+ SVZ, NES+
cortex progenitors
NSCs, OPCs,
NPCs
A neural stem-cell-like origin produces higher
malignancy and drug sensitivity
Jiang et al. (51)
BCAN-NTRK; MYB-QK;
BRAFV600E
GFAP or NES astrocytes or
NPCs
A diverse set of CRISPR-mediated genomic
alterantions lead to tumorigenesis
Oldrini et al. (52)
which still counts as one of the most commonly used models for
gliomas (27).
By far, the largest use for autochthonous models in GBM
has been in the systematic dissection of the mechanisms leading
to tumor initiation. Several studies have addressed the role
of signaling pathways, validated the genetic dependencies on
individual genes, and investigated the contribution of non-
cell autonomous factors in GBM initiation (Table 1). These
studies have uncovered critical pathways in tumor initiation
and subsequent genetic aberrations found in high-grade lesions.
The unifying conclusion from gliomagenesis in autochthonous
models is that GBM is primarily driven by an intricate mix
of pro-oncogenic hits cooperating with inactivation of tumor
suppressive pathways. On the one hand, hyper-activation of the
AKT and MAPK pathways has to occur through either supra-
physiological receptor tyrosine kinase (RTK) activity (e.g., EGFR,
PDGFRA) or a loss of negative regulators, such as PTEN and
NF1. On the other hand, the Rb and p53 pathways must be
circumvented by either direct inactivation or through deletion of
the INK4A/ARF locus (also known as CDKN2A).
The cellular origin of the disease is an additional intense
area of research enabled by GEMM models. Mouse models are
useful in this endeavor because the retrospective nature of this
assessment makes it hard to precisely identify the cellular origin
of cancer in humans. The identification of metastable GBM
molecular subtypes and genetic biomarkers, however, provided
indirect evidence that fully fledged tumors potentially bear a
signature of their potential cell-of-origin (53, 54). This has
been now extended to several other cancers (55). Importantly,
data in GEMMs are consistent with this view. Overall, from a
formal literature review it emerged that: (i) different mutations
appear to dictate the cellular phenotype of the resulting tumors;
(ii) tumors with similar alterations but originating in different
cellular compartments have private biological properties (38, 43,
45, 46, 48, 56). Mouse models have produced overwhelming
evidence that undifferentiated neural stem and progenitor cells
can efficiently serve as cell-of-origin for the disease in the
experimental models (Table 1). Yet it is also evident that nearly
every cell in the mouse brain, including post-mitotic neurons,
has a potential for transformation, if the oncogenic pressure is
significant enough (44). While these studies do not necessarily
address the pathophysiological relevance of the models for the
origins of human gliomas, two strong messages have emerged
from this research. First, neural stem cells are significantly more
prone to transformation than the differentiated cells composing
the brain parenchyma. Consistently, sequencing of the human
SVZ appears to suggest that pre-transformation clones tend to
reside in the area of the human brain containing the most
undifferentiated neural progenitors (57). Second, regardless of
the cell targeted by the oncogenic signaling, the formation of
a glial-like malignant progenitor population appears to be an
obligatory step in the malignant transformation.
Despite the sophisticated and elegant approaches that were
used to generate GEMMs for glioma, the implications of these
findings for therapy have so far been limited. Cell cycle regulation
emerged as a major predictor of therapeutic response (51, 58),
a finding that does not offer additional therapeutic options per
se, but represents important ground for future glioma modeling.
As discussed below, these studies provide enhanced confidence
in transplantation models generated by transforming normal
primary cells.
Recently, improved genetic engineering delivery and effectors,
such as the CRISPR/Cas9 system have opened new routes
to modeling human tumors, including gliomas. CRISPR/Cas9
operates via either non-homologous end joining (NHEJ) that
generates genome deletions and insertions (indels), or by
homology directed repair (HDR). This approach permits a
direct genetic engineering of endogenous loci thereby avoiding
random genome integration and potential genotoxicity, which
is the intrinsic risk associated with retroviral delivery. For
instance, in utero electroporation of gRNAs and Cas9 allowed
the simultaneous in vivo deletion of the Trp53, Pten, and Nf1
tumor suppressor genes directly in the brain. This approach
bypassed tedious modifications at zygote level (47). Considering
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that Trp53 and Nf1 are located in close proximity to each other
in the genome, conventional breeding is unlikely to produce
mutants through their separation onto different chromatids
during chromosomal crossover without very time-consuming
efforts. This illustrates one way for CRISPR/Cas9 to significantly
speed up the pace at which disease models can be generated,
including cancer (reviewed, among others, by Sanchez-Rivera
and Jacks) (59). Most likely, other investigators will quickly adopt
in vivo electroporation.
In addition to simplifying single gene modifications,
CRISPR/Cas9 has permitted the modeling of complex
karyotypes. For instance, CRISPR/Cas9 was instrumental
to generate the mouse equivalent of fusion proteins previously
discovered in human cancers (49). The intracranial adenoviral
delivery of CRISPR/Cas9 directed microdeletions in the genomic
loci of Bcan and Ntrk1 (Brevican and Neurotrophic Receptor
Tyrosine Kinase 1, respectively), led to the generation of a mouse
model for glioma in which tumorigenesis is driven by BCAN-
NTRK1 fusion. This model demonstrated a good response to
the kinase inhibitor Entrectinib, which preferentially targets
tropomyosin receptor kinases, including NTRK1 (49). This
report by the Ventura lab builds on their own pioneering work in
generating an EML4-ALK fusion model for NSCLC (60), using
CRISPR/Cas9 to systematically screen for fusions as oncogenic
drivers in solid tumors. Using this approach, in addition to the
chromosomal deletion required for the Bcan-Ntrk1model, it has
been possible to model the Myb-Qk chromosomal translocation
as well as induce an equivalent of the human BRAFV600E
point mutation by homology-directed-repair (52). The latter
improvements in genetic engineering now make easier to
generate more complex genotypes in autochthonous models. For
instance, mutations in the Isocitrate dehydrogenase 1 (IDH1) are
associated with a number of blood and solid tumors, including
GBM. While a IDH1R132H models were generated before using
classic transgenesis (61, 62), the ability of modifying single loci
or create large chromosomal deletions paves the way to generate
autochthonous models for human gliomas based on 1p/19q,
IDH, and TERT Promoter Mutations, which represent specific
entities in humans (63, 64).
Collectively, these studies support GEMMs as invaluable
tools in exposing the principles underlying glioma genetics and
biology. Non-autochthonous models (described below) have a
different set of advantages but clearly GEMMs stand to gain even
more momentum in the CRISPR/Cas9 era.
Transplantation Models for Glioma
Transplantation models represent the most widely used
alternative to GEMMs, and are essentially built using cells
endowed with the ability to initiate tumors in secondary
recipient animals. This modeling approach offers the flexibility
of spatiotemporal control on tumor initiation and of the potential
to experimentally manipulate individual cells. The impact of
such manipulations, in turn, can be tested competitively during
tumor growth or response to treatment.
The implantation can be carried out in either the tissue in
which the disease originated (orthotopic), or more accessible
locations, such as the flank of a recipient animal. The choice of the
tumor cell and the recipient animal defines whether a model is to
be considered syngeneic, homotypic, heterotypic or xenogeneic.
For instance, the transplantation of GL261 mouse glioma cells in
C57BL/6 recipient mice is considered syngeneic, because GL261
also have a C57BL/6 genetic background. If the background
of the donor and recipient animas is not identical, the model
is defined as homotypic. A transplantation mode is defined as
xenotransplantation if the genotype of the donor is from humans,
whereas it is heterotypic for genomes from every species other
than humans. Transplantation-based models represent a trade-
off between limitations on the pathophysiological relevance and
an enhanced control over the temporal initiation of the disease as
well as the unique feature of permitting perturbation experiments
of various types. Since the first transplantation experiments in
nude mice (65, 66), transplantation has permitted testing the
tumorigenic and developmental potential of glioma, dissecting
its heterogeneity and characterizing underlying molecular
mechanisms. Given the flexibility and scalability of this system,
it is the best choice for individual target discovery and validation
as well as for developing disease-relevant systematic discovery
platforms in vivo.
Syngeneic Transplantation Models
Syngeneic tumor models have widely used GL261 cells, due to
the fact that they exhibit key alterations in RAS, p53 and PI3K
and other pathways which are commonly deregulated in human
GBM. Tumors generated in this way share features with human
GBM including the upregulation of VEGF and HIF-1α and a
diffuse invasion pattern while retaining an intact immune system
(67). Lately, syngeneic models have regained more attention with
the increasing focus on cancer immunotherapy.
Evidence in cancer patients and mouse models have
substantially supported that tumors can be immunogenic but
also induce acquired immune tolerance (68). Thus, with the
exception of tumors with high mutational and neoantigen load,
such as melanoma and lung cancer (69), in heterogeneous solid
tumors, the immune-checkpoint inhibitors are unlikely to be
effective as single agents. Syngeneic models are well-positioned to
evaluate the efficacy of combination therapies, which include the
immunotherapy component. In gliomas, one viable combination
therapy tested in syngeneic models is the efficacy of CAR T-cells
(i.e., T-cells expressing chimeric antigen receptors) with the
standard-of-care (70). In a transplantation setting, syngeneic
splenocytes from C57BL/6 or VM/Dk were directed against GL-
261 or SMA-497, SMA-540, and SMA-560 cells, respectively,
by using the full-length NKG2D protein fused to CD3. This
system has the advantage of targeting poorly expressed antigens,
which is therefore better systemically tolerated. Moreover,
NKG2D ligands are multiple antigens, therefore making it
more difficult for the tumor to escape. Finally, NKG2D
ligands expression appears to increase upon temozolomide
and radiotherapy (70, 71), making these targets particularly
attractive in an adjuvant setting. Future preclinical testing
should include metalloproteases inhibitors, since ADAM10 and
ADAM17 expression by tumor cells appear to provide a simple
solution to immunevasion by producing soluble NKG2D (72),
thereby dampening the γδ T-cell adaptive response (71).
Frontiers in Oncology | www.frontiersin.org 5 October 2018 | Volume 8 | Article 429
Gargiulo Next-Generation in vivo Modeling of Human Cancers
Training the immune system against tumor cells using
vaccines could potentially induce a long-term immune response.
In a syngeneic mouse model, dendritic cell vaccination using
glioma stem-like cells (GSCs) lysate resulted in a measurable
response in mice (73). This approach, however, is still being
perfected in the setting of human vaccination against brain
tumors, as witnessed by clinical trials that failed to show an
objective clinical response (74, 75).
Evidence from immunocompromised HIV/AIDS patients is
compatible with the speculation that the adaptive immune
system is most effective in controlling truly foreign antigens.
In fact, HIV/AIDS patients largely develop virus-associated
cancers with increased frequency but not other antigenically
“colder” tumors (76). A compelling solution to selectively induce
immune responses against foreign antigens in tumor cells is
offered by oncolytic viruses (OVs). OVs with tropism for cancer
cells can simultaneously act at different levels in the tumor
microenvironment (TME). Local killing of tumor cells works
as in situ vaccines, alerting antigen-presenting cells (APC) to
multiple tumor-associated antigens (TAAs). To contribute to
APCsmaturation, this effect can be reinforced byOVs preloading
with dedicated cargoes (e.g., GM-CSF gene as co-stimulatory
treatment). OVs can promote intratumoral T-cell infiltration, for
instance, by eliciting a type I interferon response. By inducing
local acute inflammation, OVs can also reduce the impact
of a suppressive TME. For a recent comprehensive review of
the use for OVs as anti-cancer therapy, including a list of
several clinical trials for OVs in cancer, I would refer the
reader to Twumasi-Boateng et al. (77). Recently, Measles-based
virotherapy has demonstrated synergistic activity with anti-PD-
1 therapy in GBM treatment in a syngeneic C57BL/6 GL261
model (78). In a similar setting, intravenous delivery of GM-
CSF/reovirus also showed synergistic activity with anti-PD-1.
Moreover, intravenous reovirus delivery was also performed in
human patients, and the viral payload was confirmed upon
tumor resection, providing evidence of successful induction of
the hallmarks of OVs activity (79). These examples are very
important since checkpoint inhibition alone is insufficient to
induce a response in GBM patients (80, 81). Preliminary clinical
trials on OVs approaches are now completed and report on some
positive indicators onto which more clinical and pre-clinical
research should be designed) (82, 83), thereby underscoring the
importance of animal models in testing strategies to awakening
the immune system.
Thus, syngeneic models are becoming increasingly
widespread. In addition to the mouse models, C6 glioma
implantation in the fronto-parietal lobe of Whistar rats and
9L gliosarcoma in Fisher rats display features common to the
human disease, such as proliferation, similar focal invasion as
well as pseudopalisading necrosis surrounded by cells with great
nuclear polymorphism (67). Interestingly, allogeneic 9L tumors
in Wistar rats show a high infiltration of macrophages, microglia
and CD4+/CD8+ T-cells that coexist with tumor lesions (84).
This model has been successfully used to prove that dendritic cell
therapy leads to enhanced tumor infiltration by CD4+/CD8+
T-cells and prolonged survival (85), and might represent a valid
alternative to mouse models in the study of mechanisms of action
for checkpoint inhibitors or therapeutic approaches targeting
immune cells by other mechanisms, such as OVs.
Homotypic and Xenogeneic
Transplantation Models
Traditionally, transplantation-based models served the purpose
of testing the genetic dependence of tumor cells on individual
genes or pathways (Table 2).
While C6 tumors bear alterations in key tumor suppressors,
such as the Cdkn2a (Ink4a/Arf ) and Pten, in syngeneic as well
as allogeneic transplantations, the transformation of astrocytes
and neural stem cells derived from tumor suppressor mutant
animals provides higher control of the tumor genotype (94), and
represents a better setting for target discovery and validation
(100).
A transplantation model based on immortalized astrocytes
was instrumental in demonstrating that the loss of both the
p53 and pRb pathways and gain of MAPK signaling and
TERT-dependent telomeres protection are critical components
in gliomagenesis (88). In the mouse, the minimal combination
of the Ink4a/Arf locus deletion (i.e., p53 and pRb pathway
inactivation) and constitutive EGFR activation by a glioma-
specific mutant (i.e., MAPK activation) is dominant over the
cell of origin (89). These seminal discoveries anticipated the
demonstration that telomere protection can be reactivated
by multiple means. TERT is reactivated, for example, in
patient-derived glioma cells propagated under neural stem cell
conditions, suggesting that upstream signaling can suffice (93).
Moreover, there also exists a mechanism for the alternative
lengthening of telomeres in GBM patients (101). Hence, while
the control of telomere integrity is critical to gliomagenesis,
TERT overexpression in itself may be a dispensable genetic
manipulation in the process of glioma modeling in the mouse,
despite promoter mutations define specific entities in human
gliomas (63, 64).
Despite the fact that transplantation-induced stress can
impart clonal expansion and affect gene expression, orthotopic
transplantation should be considered the best approximation for
a transplantation setting. In fact, subcutaneous and orthotopic
growth impart very different transcriptional responses to the
glioma cells’ in vivo gene expression profile and response
to treatment (91, 102). Consequently, orthotopic models for
glioma also played a major role in the quest for potential
epigenetic anti-cancer targets. The Polycomb group (PcG)
gene Bmi1 was shown to have oncogenic functions in
gliomagenesis as a negative regulator of the Ink4a/Arf tumor
suppressor as well as Ink4a/Arf -independent functions, as
found in both mouse and human cells (94, 103). Likewise,
the Polycomb repressive complex enzyme EZH2 also appeared
to be required for glioma cell survival and proliferation
in grafting experiments (104) and might be a good target
reinforcing the adjuvant chemotherapeutic agent Temozolomide
(99), even though context-dependent effects in the opposite
direction were observed (105). Considering that Polycomb
proteins contribute to coordinate the transcriptional response to
converging pathways (100), the differential response to Polycomb
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inhibition may reflect the contribution of context-specific stress
pathways within individual experimental settings. Alternatively,
or in parallel, multiple cell populations composing the intra-
tumoral mass may be differentially sensitive to Polycomb
inhibitors (106), and their relative abundance may determine the
overall response to the single agent.
To date, the genetic pathways that have been shown
to prominently contribute to glioma growth in orthotopic
mouse models have been largely validated by genomic studies
in human patients (107), whereas targeting the epigenetic
machinery as anti-cancer strategy still awaits the identification of
effective combinations to account for compensatory mechanisms
including adaptive responses and intra-tumoral heterogeneity.
Dissecting the tumorigenic potential of individual cellular
populations that reflect this heterogeneity have also largely relied
on the use of orthotopic models (Table 2). Following pioneering
studies in leukemia (108), Dirks and colleagues demonstrated
that tumor initiating ability in Non-obese diabetic, severe
combined immunodeficient (NOD-SCID) mice is restricted to
a subset of brain tumor cells (90). These cells in human GBM
could be prospectively isolated using CD133 as surface marker
(90). The ability to form neurospheres in vitro (109), and to
withstand ionizing radiation (92) are critical biological features
associated with “cancer stem-like cells” from high-grade gliomas.
Surface markers, such as CD15 and CD44 have also been used
to positively enrich for brain tumor initiating cells (96, 110).
However, systematic comparisons of orthotopic grafts generated
in CD1 Nude mice using glioma cell populations with different
profiles of surface markers revealed that the non-enriched
population also has tumor-initiating ability, with delayed growth
kinetics (97). The difference for heterogeneous tumors, such
as GBM may reflect the trans-differentiation ability of tumor
cells into a wide range of lineages (111–114). Rather, the neural
stem cell growth conditions of primary GBM cells proved to be
a critical determinant in how accurately the orthotopic grafts
resembled the patients’ tumors (93, 95, 115). Collectively, these
studies made enormous contributions to uncovering the cellular
components of intra-tumor heterogeneity and highlighted the
importance of orthotopic xenograft models.
Xenotransplantation is becoming increasingly the setting of
choice for high-throughput target discovery and validation, a
research area that recently evolved around the use of orthotopic
models for cancer. Several pioneering studies in various allograft
transplantation models have highlighted the importance of
genetic screens in relevant physiological contexts (116–118). To
cope with the numerical limitations imposed by the in vivo
setting (119), genetic screens using RNAi in gliomagenesis (100,
120) were performed in immunocompromised animals with
small libraries, or a genome-wide CRISPR was performed first
in vitro and followed later by a parallel in vivo/in vitro validation
screen (121).
As inferred by these studies, the use of immunocompromised
recipient animals remains an invaluable tool in investigating
cell autonomous mechanisms in human cancer cells in vivo
and the choice of cellular models is therefore critical. Tumor
models using established tumor cell lines have enormously
contributed to our knowledge of tumor biology but are
increasingly being dismissed in gliomagenesis experiments (122).
The state-of-the-art in the field of brain tumors is to propagate
tumor cells under conditions supporting non-transformed the
in vitro self-renewal of neural stem cells (93). Limitations to
this approach include that: (i) ex vivo propagation remains
anchored to the assumption that signaling, supplements and
environmental conditions are known and can be delivered
homogeneously, (ii) some low-grade tumors as well as specific
genotypes systematically drop out in these conditions (123).
Nonetheless, sophisticated ex vivo culture conditions represent
the best approximation to preserve tumor identity while enabling
experimental manipulations or in vitro screening endeavors
(115). Indeed, when compared to patients’ biopsies, conventional
glioma cell lines fall short of representing patients’ molecular
profiles (53).
Patient-Derived Xenografts Models
An elegant approach to bypass cultures while focusing on patient-
oriented modeling is to generate Patient-derived xenografts
(PDX) or Avatar models, created by patients’ biopsies without
applying ex vivo culturing prior to transplantation (124). PDX
models propagate the complex cellular and genetic heterogeneity
of the cell surviving in the host animal, and are therefore capable
of modeling responses to standard, targeted or combination
therapies without forcing assumptions on the tissue sample. A
variant to preserving patients’ biopsy tissue structure is dissecting
the tissue prior to the transplantation of live cells. This is
usually exploited to bypass the low take rate for some tumors,
a drawback affecting low-grade or high complexity tumors.
A similar approach is used to perform limited experimental
manipulations followed by serial transplantation (99).
There is a general consensus that PDX models maintain some
level of concordance between patients and PDX responses to
therapy (125, 126). This includes GBM, which partly preserves
molecular profiles principles during xenotransplantation
(53, 127). Importantly, however, the response to anti-cancer
treatment largely depends on the tumor cell genotype at the time
of the treatment (127). The latter piece of evidence is relevant
in that both ex vivo cellular passaging and PDX intrinsically
suffer a drift toward genomic instability. In a recent large-scale
study, the dynamics of copy number alterations (CNAs) in 1110
patient-derived samples of different cancer types during multiple
rounds of in vivo propagation have been reported. A high rate
of CNAs was observed in xenografts that artificially drift away
from the human counterpart. For instance, glioblastoma patients
acquire extra copies of chromosome 7 during tumor evolution,
whereas PDX propagation in mice results in a loss of these extra
copies. While the genetic drift is not surprising for malignant
gliomas given their near-complete deficiency in DNA damage
checkpoint control (128), these results raise awareness of the
limitations associated with the use of PDX as patients’ avatars
to evaluate their responses to any given therapy and call for
integrating this resource with more stable models (129). It is also
critical to realize that responses to therapies in PDX models will
be affected by the intra-cellular heterogeneity of the transplanted
tumor. Using an elegant cellular barcoding strategy, the Dirks lab
has recently demonstrated that a number of different cancer cells
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within a tumor can contribute to its homeostasis (99). Strikingly,
however, this number can change from one tumor to the next,
thereby affecting the reproducibility of hypothesis testing or
target discovery and validation experiments.
In immune-oncology, transplantation models are the
preferred choice when testing the impact of innate immune
checkpoint inhibition and CAR T-cells. For instance, disruption
of the CD47/SIRPα signaling affects leukemia, glioma, melanoma
and hepatocellular carcinoma growth as xenografts (98, 130–
132). The efficacy of GD2-CAR T-cell against glioma cells was
pre-clinically tested in NSG mice until the onset of graft-vs-host
disease symptoms (GvHD; ∼4 weeks), and GD2-CAR T-cells
are currently tested in several clinical trials (among others, see
NCT03252171).
These studies collectively highlight the continuing process
of addressing the intrinsic challenges associated with
transplantation models and expanding these to advanced
pre-clinical settings, anticipating that this experimental system
will retain its leading role in experimental medicine.
Next-Generation Autochthonous Models
In mice, the CRISPR revolution will make the generation of
complex animal models increasingly easier, faster and affordable
(Figure 1).
Tumor heterogeneity and evolution is a major feature of
human cancers (133, 134), and these features have proven hard
to model autochthonously. One important consideration for the
design of future, next-generation mouse models is their genetic
background. Most mouse strains are inbred and represent a great
advantage in research to unravel specific targets or mechanisms
in a certain type of cancer (135). Yet inbred strains are far from
the real diverse setting of disease development in humans, and
the genetic background of animals used as pre-clinical cancer
models in research is critical to the outcome of the study. In
gliomagenesis, Nf1 and p53 deletion leads to a tumor grading
ranging from low-grade astrocytoma to GBM depending on the
distinct mouse strain (29). Likewise, p53 heterozygosity leads
to a spontaneous formation of mammary tumors in BALB/c
mice but not in C57BL/6J (136), suggesting a distinct pro-
tumorigenic genetic background in BALB/c mice. Moreover,
the RF/J strain displays a high incidence of cancer owing to
missensemutations in DNAdamage repair and cancer-associated
genes and may become the model of choice for genetically
hypermutated tumors, such as smoking-driven lung cancer, UV-
driven melanomas and DNA repair-deficient colon cancer. The
choice of the background for future GEMMs may be driven by
the clinical history of individual diseases and may exploit the
Collaborative Cross Consortium 2012 benchmarking of several
inbred mouse strains (137). In turn, this may also facilitate
testing the contribution of natural variation and DNA repair in
tumorigenesis and responses to treatment. This appears to be
particularly important if one considers that genetic variation may
not only affect tumor-intrinsic, but also and even more likely, the
tumor-immune phenotype.
The recent conclusion of a colossal genomic investigation
in almost 10,000 genomes spanning 33 cancer types by the
Cancer Genome Atlas (TCGA) has provided an enormous
dataset of cancer driver genes (138). In vivo validation and
hypotheses testing follow-ups are lagging behind. Simultaneously
testing dozens of putative tumor suppressors within a native
and immunocompetent microenvironment is now possible. In
a medium throughput in vivo screening in gliomagenesis using
the stereotactic injection of a sgRNA adenoviral library for
CRISPR/Cas9 mediated knock-outs, the Sidi Chen lab reported
on ability for PanCancer-defined significantly mutated genes to
initiate brain tumor formation (50). The combination of regional
viral delivery and GFAP-Cre conditional activation of Cas9 and
GFP restricted the screen to a subset of glial cells. This type of
screen follows the direct RNAi delivery pioneered by the Zender
lab in hepatocellular carcinoma (139). While the inability of AAV
to genetically integrate into the host genome requires extensive
target sequencing as direct readout, compared to earlier studies,
this provided a significant higher throughput in screening for
combinatorial signaling dependencies during gliomagenesis (38,
43). It also represented a more physiological setting for tumor
suppressor discovery than transplantation models previously
used in similar endeavors (100). Considering that adult GBM is
a disease that often develops over several years and goes through
regional and temporal evolution (140, 141), future studies along
these lines may benefit from integrating more sophisticated,
spatiotemporally precise forms of editing. Examples of the
sequential delivery of cancer driver mutations exploiting classic
genetic recombination techniques were previously reported
(142). To enable further spatiotemporal control, biochemical,
chemical or optogenetic control of tumor progression may be
employed. This would be particularly important in order to better
mimic disease initiation and progression (Figure 1).
An enhanced control of tumor progression using advanced
genetic engineering methods may permit a validation of
driver and passenger mutations as modifiers of tumor
progression and responses to therapy or testing advanced
genetics paradigms, such as genetic essentiality (22). To this
end, while direct intracranial injection of RNP complexes
has not yet been exploited in models of glioblastoma, it has
been successfully applied to genome editing in the mouse
brain (143). During brain tumor exposure to multimodal
therapy, additional aberrations in core GBM driver pathways
are acquired. Combining longitudinal intravital imaging and
topical delivery of RNPs or in situ electroporation-inducing
genetic engineering may help in elucidating the contribution
of genetics to disease recurrence. Genetic alterations identified
as critical regulators of tumor evolution could be defined
as “steering” mutations, and would become an integral part
of sequential modeling. In GBM modeling, two examples
of such mutations may be Nf1 and Msh6, both of which
are associated with recurrent tumors and TMZ-induced
hypermutations (144, 145). Importantly, this approach would
also permit the functional dissection of cell-autonomous
mechanisms, such as tumor microtube formation (146),
as well as non-cell autonomous processes, such as vessel
dysmorphia (147).
Unpredictable adaptive responses to anti-cancer treatments
are a hallmark of solid tumors. Cancer cells can evade
chemotherapy by acquiring additional mutations, switching
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FIGURE 1 | Next-generation modeling of human cancers: longitudinal single-cell “omics” in autochthonous and transplantation-based models. Upper panel: genetic
drivers of human cancer are combined with a genetic background of choice to give rise to homogenous, heterogeneous, or hypermutational tumors. Genetic
engineering can use independent genetic and/or chemical switches to permit tissue-specific and temporal control. To increase tumor heterogeneity or test the
contribution of mutations identified at recurrence upon tumor formation, intratumor injections of “steering” mutations using viral or other means can be used. These
sophisticated cancer GEMMs permit testing complex dosing treatments. Lower panel: to test genetic dependences or perform genetic screens, patient-derived or
ex vivo transformed tumor-initiating cells are genetically modified and/or barcoded and then transplanted into recipient animals. The host background can be chosen
to favor tumor take and/or drug penetration. In this setting, a co-grafting of adaptive or innate immune cells or other microenvironment players (e.g., endothelial cells,
pericytes, etc.) or serial transplantation can be implemented to study non-cell autonomous mechanisms and to exacerbate competition among cancer cells.
Heterogeneity increases as a function of time and intra-tumor complexity. Both experimental models can be exploited in longitudinal follow-ups using live imaging or
single cell “omics” (central panels). The latter approach can simultaneously generate spatiotemporal information on changes in cell cycle progression, apoptosis, cell
fate decisions/microenvironment activation (i.e., biomarker variations) and immune cell composition. Right panel: single cell preps from GEMMs or orthotopic
transplantation models can be transplanted (dashed line) in the indicated immunocompetent animals thereby creating a syngeneic/xenogeneic models, respectively.
Potential applications for these models are indicated. T0, T1, and Tn = time points for longitudinal analyzes; pseudospatial complexity refers to the output of tSNE
maps as a surrogate for spatial information. Iv, intravenous; Ic, intracranial.
to a state of negligible growth, by activating survival pathways
through changes in cell identity, and by other means. In
modeling human cancer in mice, one should account for
possible species-specific tumor genotype drifts that would
not be representative of the patients’. Thus, next-generation
GEM models that better represent primary tumors and their
evolution at a genetic level (as depicted above) will be invaluable
tools for testing complex chemotherapy-dosing schemes
(Figure 1).
Longitudinal studies in humans are revealing oncogenes
dominant in recurrence. In GBM, mutations inNF1 and PI3KCA
appear to drive disease progression (145, 148, 149), and may
be temporally controlled to mimic disease progression. In such
models, complex sequential drug combinations may be tested.
For instance, switching off NF1 or PI3KCA, which reinforce
the RAS pathway and confer sensitivity to a combination
of BRD4 and MEK inhibition (150). A neoadjuvant-like
multimodal therapy followed by targeted drugs, would be
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prototypic examples of testing complex targeting of acquired
mutations.
Metronomic chemotherapy and planned drug holidays are
complex dosing schemes that aim at reversing drug tolerance. In
GBM, tumor cells evade adjuvant Temozolomide using MGMT
reversal and cell cycle restriction. A Temozolomide holiday may
be therefore alternated with targeted therapies, such as blood-
brain-barrier penetrant PI3K inhibitors (151).
An emerging paradigm in cancer biology is to drive cancer
cells to acquire specific addictions and then targeting such
addictions with drugs. This approach may be important in
exploiting metabolic (152, 153) as well as epigenetic targets (154),
or targeting collateral lethality associated with acquired resistance
mechanisms [(155) and our unpublished data]. This includes also
extrinsicmechanisms, such as those targeted by adaptive immune
checkpoint inhibitors. Indeed, studies in syngeneic models have
shown promising results in a combination or neoadjuvant setting
that induced PD-L1 expression (79, 156).
While complex dosing schemes have been so far directly
tested during clinical trials, the combination of accurate GEM
models and complex readouts should make it standard practice
at the pre-clinical level to test whether low-dose or sequential
treatments are equally or even more effective than drug
combinations, thereby sparing patients from the side effects of
the added toxicity and possibly enhancing tumors’ response. In
this regard, once the specie-specific differences are accounted
for, the autochthonous models are well-positioned to provide the
most physiological setting for tumor initiation and organismal
response to treatments.
Next-Generation Transplantation Models
Transplantation models are currently developing on parallel
research lines.
To avoid the complications of genetic drifts as well as
patient-specific passenger mutations, PDX xenograft models are
being complemented with de novo transforming human cells
derived from normal tissue with relevant cancer mutations in
the projected neoplasia. Transforming human astrocytes has
been instrumental in formally testing the contributions of the
main pathway required for efficient gliomagenesis in human
cells. Recent work using human colon organoids has shown that
combining an appropriate cell of origin and set of mutations is
still insufficient to recapitulate some of the biological properties
of the true tumors, such as metastasis (157). Future work in this
direction should be aimed at precisely dissecting genotype-to-
phenotype connections in human cancers using advanced genetic
screening systems. In this regard, systematically transforming
normal mouse and human cells to create next-generation avatar
models is expected to help address some open questions. For
instance, in numerous solid tumors, the role of copy number
aberrations remains to be clarified. Whereas, human GBM is
clearly a disease of copy number aberrations (158), studies in
autochthonous models so far fall short of clarifying whether
and how this feature contributes to the disease. Moreover,
emphasis should be given to developing an understanding of
molecular phenotype specifications for tumors including GBM in
which there is limited evidence of genetically encoded subtypes.
Overall, creating reliable and homogenous tumor-initiating cells
in vitromay complement PDX-models and permit testing ad hoc
biological questions as well as providing a more reproducible
resource for target discovery and validation (Figure 1).
The recipient animals are a critical determinant of the success
of transplantation models. The informative value of such models
is dependent on both cell-intrinsic and non-cell autonomous
components. On the one hand, achieving the highest grafting
potential through the use of severely immunocompromised
animals is the essence of xenotransplantation (159). On the
other, the discovery of adaptive checkpoint inhibitors and the
need to identify the basis for responses to immunotherapy
pose additional challenges to modeling human tumors
using xenotransplantation; one solution is to reinstate the
adaptive immune system in host recipients. Freshly isolated
peripheral bone marrow cells (PBMCs) or specific immune
cell subpopulations can be co-grafted with human cancer cells
subcutaneously in immune deficient animals (e.g., NSG/NOG).
Alternatively, PBMCs can be parentally infused (i.p. or i.v.) after
subcutaneous or orthotopic tumor transplantation has taken
place. This approach revealed, for instance, the immunogenic
effect of a Carcinoembryonic Antigen CD3 T-Cell Bispecific
Antibody (CEA-TCB) in promoting the infiltration of xenografts
as well as adaptive PD-L1 over-expression, thereby suggesting
the feasibility of combining its administration with adaptive
immune-checkpoint inhibitors (160). Whereas this setting is
limited to short-term studies given the potential for severe GvHD,
it also enabled assessments of the efficacy of immunotherapies
and the impact of T-cell subpopulations (e.g., regulatory T-cells;
T-regs) or antigen-presenting cells (APC) on the activation of
cancer cells (161).
The GvHD is not only a complication for the recipient
animals. Immune cells that suddenly face a full-blown
tumor to which they were previously naïve face an acute
pathophysiological stimulation reflecting the actual tumor.
Ideally, future models will feature intact innate and adaptive
immune systems trained to ignore the grafting phase and
triggered by pathophysiological stimuli to transiently allow
grafting. An elegant example of this approach in glioma
models has been achieved by blocking the T-cell activation
by APC through CTL4A-IgG (clinical name: Abatacept) and
anti-CD154. Immune-tolerant mice generated by this approach
developed GBM lesions and these affected survival with similar
kinetics as immune-deficient animals (162). As an alternative
in immune-deficient backgrounds, co-grafted immune cells
may be pre-exposed to tumor cells (e.g., DC loading with
tumor cells lysate or RNA), thereby more closely mirroring
the gradual rise of tumors in humans. Moreover, some innate
immunity players may require specific co-grafting schemes. For
instance, microglia cells, the resident macrophages of the central
nervous system, are generated during embryonic development
(163). These cells are associated with the full specification of
the Mesenchymal GBM subtype identity (164–166), and most
likely with responses to treatment (167). This situation calls for
a reliable source of human microglia whether tumor-isolated
or in vitro immortalized to serve as co-grafting partners in
transplantation models.
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The genetic engineering of recipient animals can also be
exploited to selectively impair the tumor microenvironment.
To determine the role of drug penetration and reabsorption in
brain tumor models, for instance, the drug transporters ABCB1
and ABCG2 were deleted not only in wild-type glioma models,
but also in immunodeficient recipients in xenotransplantation
models (168, 169).
In the neurosciences, the rat is the experimental and
translational model of choice wherever possible. This species
is considered superior for etiological, pathophysiological,
pharmacological and behavioral studies (170). The discovery of
culture conditions that facilitate the expansion of rat embryonic
stem cells as well as the direct use of CRISPR during zygote
formation may enable extending also to rats the generation of
complex models for gliomas. This would allow extending the use
of these animals from a limited pharmacodynamics setting to a
fully-fledged advanced modeling system.
The future development of transplantation models at the
levels of both tumor cells and recipient animals will enable more
sophisticated experimental dissections of cell-intrinsic and non-
cell autonomous mechanisms and a more effective platform for
target discovery and validation.
Outlooks and Perspectives for Single Cell
“Omics”
Interrogating cell cycle responses, apoptosis and cell identity
drifts at the level of single cells is a transformational change
in that it permits assessing the effects of a compound
and simultaneously to build hypotheses based on possible
combinatorial treatments or sequential treatments (Figure 1).
Single-cell RNA sequencing has been significantly exploited in
GBM to describe intratumor heterogeneity and the peculiarities
of GBM subtypes and their microenvironments (164–166). This
approach has also been instrumental in identifying genetic
and transcriptional identities associated with tumor-specific
biological properties, such as proximal and distal recurrence,
infiltration and numbness to the fluorescence-guided probe for
the resection of diseased tissue (5-Aminolevulinic acid, also
known as 5-ALA) (149). DNA methylation is being currently
implemented in clinical neuropathological practice for brain
tumor classification (171). The availability of technologies
enabling to simultaneously generate single cell RNA-seq (scRNA-
seq) and bisulfite-converted DNA methylation (BS-seq) maps
from the same cell (172) has a potential to allow the tracking of
tumor responses to treatments. In turn, this will be a major driver
in the development of targeted therapies in both autochthonous
and transplantation models (Figure 1).
I envision that the combination of multiple autochthonous
models in parallel and scRNA-seq and BS-seq may be exploited
to evaluate the way the core tumor and in the infiltrating margins
respond to individual treatments. Importantly, metabolic
labeling of RNA in vivo now enables identifying faster and more
accurately the adaptive transcriptional changes (173).
To bridge preclinical and clinical testing, longitudinal scRNA-
seq in GEMMs may help assessing and improving adjuvant and
second-line treatments. To some extent, autochthonous models
of aggressive human cancers may well represent low Karnofsky
performance score (KPS) patients or very hard-to-resect tumors,
in that surgery is discouraged. In these cases, single cell
profiling will be very informative in testing the consequences
of standard approaches, such as radiation followed by adjuvant
treatments (e.g., in GBM, Temozolomide, Bevacizumab) and
provide benchmarks for new treatments. This matter has so far
been restricted to advanced clinical trials in patients and may be
now repositioned at the preclinical stage.
Exceptionally, single cell “omics” and autochthonous models
may also help testing next-generation probes for optically
guided surgery. 5-ALA is currently used in fluorescent-guided
surgery to delineate tumor margins for resection, which is
extremely important in preventing local recurrence in the
brain parenchyma, where surgeons need to be conservative.
Recent studies in GBM at the single-cell level suggest that
5-ALA appears to mark Mesenchymal subtype-specific GBM
cells, leaving behind Proneural-subtyped cells (149). It will be
important to test this in autochthonous models in which the
two states can be modeled (56), and to compare 5-ALA to novel
fluorescent probes. By resecting a tumor margin pre-labeled with
such probes, single cell profiling will reveal the identity of each
cell that retain or miss the labeling.
The xenogeneic transplantation setting is well-versed for
testing intrinsic cellular responses to novel treatments and
detecting adaptive resistance, notably in cases in which tumor
perfusion is homogeneous. Indeed, the response to intracellular
targets for drugs are best assessed in human cells when on-
target and off-target effects need to be accounted for. Moreover,
applying CRISPR screens to transplantation models using
scRNA-seq readouts, such as CROP-seq (174) may improve
the resolution of in vivo functional screens, thereby increasing
their throughput. In the brain tumor setting, these were limited
so far to a few dozen targets (100, 120), and CROP-seq may
lead to more comprehensive screens without compromising the
pathophysiology of the orthotopic transplantation setting (119).
Importantly, even in the absence of functional perturbations,
approaches like CROP-seq coupled with scRNA-seq will enable a
next-generation of cellular barcoding experiments to trace in vivo
tumor homeostasis and responses to treatments (99). In this
area, PDX models should more systematically be complemented
with de novo transforming human cells and with models better
representing tumor molecular profiles.
Harnessing the therapeutic potential of the TME and
immuno-oncology will significantly benefit of building
experimental consensus within the community. In particular,
it is critical to define the appropriateness of any given model
in the assessment of the response to treatment of established
tumors. Differences between animal models and humans
specifically involve protein-coding genes and cis-regulatory
DNA due to specie-specific adaptive selection, notably those
controlling immunity (175, 176). Moreover, the consistency in
the response of human cells to mouse supplements and vice
versa (e.g., growth factors, cytokines, etc.) are largely anecdotal.
Nevertheless, whether GEMMs, syngeneic or xenogeneic models
based on orthotopic transplantation may be used for testing of
TME- and immune-therapies should be systematically assessed
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when appropriate readouts can be faithfully reproduced in
both species. This has been possible, for instance, in the quest
for identifying antigen-specific TCRs. In this case, comparing
immune-deficient mice reconstituted with human hematopoietic
progenitors (i.e., humanized mice) and mice transgenic for the
human TCRα and TCRβ loci returned similar results (177).
Despite the acknowledged pathophysiological relevance of
GEMMs, syngeneic models based on established cell lines
have been preferred in investigating TME- and immune-
therapies (Table 2). To exploit the CRISPR/Cas9 potential
in the future models, I anticipate that primary tumor cells
from sophisticated GEMM models may soon replace cell lines
in a secondary syngeneic orthotopic setting. This way, one
could harness the genetic and spatiotemporal controls in an
immune-tolerant setting (Figure 1, right panel). This approach
would be the ideal development for the preclinical dissection
of intrinsic, acquired and non-cell autonomous resistance
mechanisms. In the example provided by the combinatorial or
neoadjuvant OVs treatment, syngeneic models may be used to
uncover the mechanism conferring residual resistance, which is
indicated by the incomplete penetrance of the sensitization to
checkpoint inhibitors (79, 156). Longitudinal scRNA-seq may
reveal the optimal timing for starting the immune-checkpoint
inhibition and whether cell intrinsic or other cells from the
microenvironment are contributing to or preventing a fully
penetrant response.
Whereas testing immunotherapy strategies in
immunodeficient animals appears counterintuitive, the use
of NSG mice emerges as the mainstream strain for studies
involving sophisticated reagents eventually used in clinical trials.
These include systems for T-cells engineering (178, 179), and
innate immune checkpoint inhibitors (98, 130–132). While
retaining a leading position in these experiments, a foreseeable
evolution of this system will involve improving the recipient
animals, including transplanting human cells into highly
immunodeficient rats.
Transformative technologies, such as CRISPR/Cas9 and
single-cell genomics have opened new avenues in the study
of tumor biology. Here I propose that the longitudinal
dissection of tumor responses in animal models can capitalize
on single cell genomics approaches. The specific examples I
have discussed here are cases that could clearly improve our
current understanding of human cancers and their responses
to treatment. Combining genetic engineering and single-
cell genomics with the individual strengths of GEM and
transplantation models is bringing about novel next-generation
platforms for understanding tumor biology and for target
discovery and validation.
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